An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
Completed · Phase 2
Conditions studied: Parkinson's Disease Psychosis
In brief
This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).
Key facts
- Study ID
- NCT01518309
- Run by
- ACADIA Pharmaceuticals Inc.
- People needed
- 39
- Starts
- 2004-11-17
- Expected to finish
- 2013-05-02
- Last updated by the study team
- 2020-11-23
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study site — Danbury, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.